Analyst Stefan Quenneville of Morningstar says Vertex Pharmaceuticals Incorporated (VRTX) is an attractive larger-cap name within his coverage universe, as the company has a large opportunity in the cystic fibrosis market.
“It’s actually still an unprofitable company,” Quenneville said. “People are well aware of the opportunity in cystic fibrosis for the company. We think this is a really big attractive market, and Vertex is going to do quite well in the space.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Quenneville says Vertex is combining two of its drugs, which is up for approval in the middle of 2015. He believes Vertex will get a strong price for the combination, and that it will be a very successful launch.
“It’s a very attractive name, and it’s a company that’s developing a very strong franchise in cystic fibrosis. I don’t think there are going to be a lot of people that will be able to compete with them once Vertex really gets established and takes hold in the market,” Quenneville said.
Vertex Pharmaceuticals Incorporation (VRTX) Has High Success Levels with Novel Cystic Fibrosis Drugs
November 24, 2014
Vertex Pharmaceuticals Incorporated (VRTX) Adheres to Business Strategy to Continue Success in Biotechnology Space
July 09, 2013
Merck (MRK), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD) Trailblaze Hepatitis C Therapies
September 20, 2012
Samsung Electronics Co., Ltd. (KRX:005930) Galaxy Smartphones Take Market Share Away from Competitors
June 24, 2013
U.S. Silica Holdings Inc (SLCA) To Take Additional Market Share in 2014 and 2015
January 10, 2014
